Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Abstract

Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipilimumab alone. In patients with PD-L1-negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone. (Funded by Bristol-Myers Squibb; CheckMate 067 ClinicalTrials.gov number, NCT01844505.).

Keywords

Affiliated Institutions

• Odense University Hospital DK
• The Netherlands Cancer Institute NL
• Royal Marsden Hospital GB
• Hospital General Universitario Gregorio Marañón ES
• The University of Melbourne AU
• University of Utah US
• Trans Tasman Radiation Oncology Group AU
• University of Zurich CH
• Huntsman Cancer Institute US
• Yale New Haven Hospital US
• Yale University US
• Aix-Marseille Université FR
• Yale Cancer Center US
• Singleton Hospital GB
• Blacktown & Mount Druitt Hospital AU
• Melanoma Institute Australia AU
• University of Siena IT
• Peter MacCallum Cancer Centre AU
• Smilow Cancer Hospital US
• Bristol-Myers Squibb (United States) US
• European Institute of Oncology IT
• University Hospital of Zurich CH
• Hotel Dieu Hospital CA
• The Maria Sklodowska-Curie National Research Institute of Oncology PL
• University of Colorado Denver US
• University of Michigan US
• Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" IT
• Dana-Farber Cancer Institute US
• The University of Sydney AU
• Cornell University US
• Memorial Sloan Kettering Cancer Center US
• Mater Hospital GB

Related Publications